Amarin Corporation plc

NASDAQ (USD): Amarin Corporation plc (AMRN)

Last Price

0.572

Today's Change

+0.004 (0.70%)

Day's Change

0.565 - 0.583

Trading Volume

1,044,308

Profile
AMRN

Exchange:  NASDAQ Global Market NASDAQ Global Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. Aaron D. Berg Mr. Aaron D. Berg

Full Time Employees:  275 275

IPO Date:  1993-04-01 1993-04-01

CIK:  0000897448 0000897448

ISIN:  US0231112063 US0231112063

CUSIP:  023111206 023111206

Beta:  1.93 1.93

Last Dividend:  0.00 0.00

Dcf Diff:  0.82 0.82

Dcf:  -0.24 -0.24

Description

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Address

Grand Canal Docklands,
Dublin, 2, IE

353 1 669 9020

http://www.amarincorp.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment